Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

about

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.

P2860

Q41603225-01871EA0-17E1-43B3-8740-DF9F327BAED2

P2860

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

Item

http://www.wikidata.org/entity/Q36068850

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@ast

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@en

type

Item

label

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@ast

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@en

prefLabel

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@ast

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

@en

P1476

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review

@en

P2093

Andrew Sharabi

http://www.w3.org/2001/XMLSchema#string

Chih-Han Lee

http://www.w3.org/2001/XMLSchema#string

Kaveh Zakeri

http://www.w3.org/2001/XMLSchema#string

Loren K Mell

http://www.w3.org/2001/XMLSchema#string

Ruben Carmona

http://www.w3.org/2001/XMLSchema#string

Saif Borgan

http://www.w3.org/2001/XMLSchema#string

Zaid Marhoon

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Gene expression profiling predicts clinical outcome of breast cancer

Two-sided confidence intervals for the single proportion: comparison of seven methods

Publication bias in clinical research

A note on competing risks in survival data analysis

Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns.

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Gene-expression-based prognostic assays for breast cancer.

Cancer biomarkers: selecting the right drug for the right patient.

P304

e0156489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0156489

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Garrett Green

P5008

ScienceSource

P577

2016-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27383192

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

tumor biomarkers

biomarker

P932

4934683

http://www.w3.org/2001/XMLSchema#string

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

about

P2860

P2860

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932